123 related articles for article (PubMed ID: 31891240)
1. Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment.
Li Y; MacGorman K; Liu L; Chen J; Hoffmann M; Palmisano M; Zhou S
Clin Pharmacol Drug Dev; 2020 Oct; 9(7):785-796. PubMed ID: 31891240
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
Ogasawara K; MacGorman K; Liu L; Chen J; Carayannopoulos LN; Zhou S; Palmisano M; Li Y
J Clin Pharmacol; 2019 Dec; 59(12):1620-1631. PubMed ID: 31172535
[TBL] [Abstract][Full Text] [Related]
3. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.
Rasco DW; Papadopoulos KP; Pourdehnad M; Gandhi AK; Hagner PR; Li Y; Wei X; Chopra R; Hege K; DiMartino J; Shih K
Clin Cancer Res; 2019 Jan; 25(1):90-98. PubMed ID: 30201761
[TBL] [Abstract][Full Text] [Related]
4. Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies.
Hatake K; Chou T; Doi T; Terui Y; Kato H; Hirose T; Seo S; Pourdehnad M; Ogaki Y; Fujimoto H; Hagner PR; Yamamoto K
Cancer Sci; 2021 Jan; 112(1):331-338. PubMed ID: 33075165
[TBL] [Abstract][Full Text] [Related]
5. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
[TBL] [Abstract][Full Text] [Related]
6. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Carpio C; Bouabdallah R; Ysebaert L; Sancho JM; Salles G; Cordoba R; Pinto A; Gharibo M; Rasco D; Panizo C; Lopez-Martin JA; Santoro A; Salar A; Damian S; Martin A; Verhoef G; Van den Neste E; Wang M; Couto S; Carrancio S; Weng A; Wang X; Schmitz F; Wei X; Hege K; Trotter MWB; Risueño A; Buchholz TJ; Hagner PR; Gandhi AK; Pourdehnad M; Ribrag V
Blood; 2020 Mar; 135(13):996-1007. PubMed ID: 31977002
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment.
Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1133-41. PubMed ID: 26526983
[TBL] [Abstract][Full Text] [Related]
8. First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.
Ye Y; Gaudy A; Schafer P; Thomas M; Weiss D; Chen N; Liu L; Xue Y; Carayannopoulos L; Palmisano M
Clin Pharmacol Drug Dev; 2021 May; 10(5):471-485. PubMed ID: 32969202
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
Tomkinson H; Kemp J; Oliver S; Swaisland H; Taboada M; Morris T
BMC Clin Pharmacol; 2011 Mar; 11():3. PubMed ID: 21414193
[TBL] [Abstract][Full Text] [Related]
11. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
Tayo B; Taylor L; Sahebkar F; Morrison G
Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
Martin DE; Chapelsky MC; Ilson B; Tenero D; Boike SC; Zariffa N; Jorkasky DK
J Clin Pharmacol; 1998 Feb; 38(2):129-37. PubMed ID: 9549643
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
.
Gardin A; Dodman A; Kalluri S; Neelakantham S; Tan X; Legangneux E; Shakeri-Nejad K
Int J Clin Pharmacol Ther; 2017 Jan; 55(1):54-65. PubMed ID: 27841151
[TBL] [Abstract][Full Text] [Related]
15. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment.
Marbury T; Lawitz E; Stonerock R; Gonzalez M; Jiao J; Breeding J; Haqq C; Verboven P; Stieltjes H; Yu M; Molina A; Acharya M; Chien C; Tran N
J Clin Pharmacol; 2014 Jul; 54(7):732-41. PubMed ID: 24374856
[TBL] [Abstract][Full Text] [Related]
16. An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.
Moore KT; Vaidyanathan S; Natarajan J; Ariyawansa J; Haskell L; Turner KC
J Clin Pharmacol; 2014 Dec; 54(12):1407-20. PubMed ID: 24964176
[TBL] [Abstract][Full Text] [Related]
17. Effect of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intravenous Rivipansel.
Tammara BK; Ryan K; Plotka A; Shafer FE; Wei H; Readett D; Fang A; Korth-Bradley JM
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):918-928. PubMed ID: 32579796
[TBL] [Abstract][Full Text] [Related]
18. Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function.
Yu Y; Hoffman J; Plotka A; O'Gorman M; Shi H; Wang D
Cancer Chemother Pharmacol; 2020 Dec; 86(6):701-710. PubMed ID: 33037918
[TBL] [Abstract][Full Text] [Related]
19. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]